Zelos Therapeutics Inc.

Zelos Therapeutics Inc.

September 12, 2005 11:10 ET

Zelos Therapeutics Announces Departure of Chief Executive Officer

WALTHAM, Mass. and OTTAWA, Ont.--(CCNMatthews - Sep 12, 2005) -

Zelos Therapeutics announced today the departure of its Chief Executive Officer, Robert (Duffy) DuFresne. Mr. DuFresne has served as the Company's Chief Executive Officer and as a member of the Company's Board of Directors since March 2003.

"Since joining the Company, Duffy has made many valuable contributions to its growth and development," said Farah Champsi, Chairperson of the Company's Board of Directors. "Under his leadership, the Company raised over $50 million in financing, significantly expanded its programs and transitioned from a preclinical company to a later stage drug development company with two active clinical programs. We are grateful for Duffy's many contributions, and wish him well in his future endeavors. The Board of Directors has commenced a search for a new Chief Executive Officer to lead our management team in the next stage of the Company's development and to help us achieve our strategic objectives."

About Zelos

Zelos Therapeutics Inc. is a private biopharmaceutical company that is developing breakthrough discoveries in Parathyroid Hormone (PTH) research. Product programs include the development of a next-generation PTH analogue, Ostabolin-C™, for the treatment of osteoporosis that is currently in Phase 2 trials and a PTH agonist for the topical treatment of psoriasis. The Company also has a collaboration with Nektar Therapeutics for the development of a pulmonary formulation of Ostabolin-C™ for the treatment of osteoporosis. Zelos maintains administrative offices in Waltham, Mass. and research facilities in Ottawa, Ontario.

Contact Information

  • Zelos Therapeutics Inc.
    Farah Champsi, 415-362-4022
    Chairperson of the Board of Directors
    or
    Jeff Courtney, 416-971-6656
    Member of the Board of Directors